Cancer Cell Therapy

**Multiple Myeloma**

- **CCT5030**
  - Phase I
  - ALLO-715 Eval
  - Anti-BCMA Allogeneic CAR T Cell Tx in Relapsed/Refractory Multiple Myeloma
  - PI: Liedtke
  - Sponsor: Allogene

- **CCT5037**
  - Phase III
  - JNJ-68284528 CAR-T Tx vs PdV or PDp in Relapsed & Lenalidomide Refractory Multiple Myeloma
  - PI: Sidana
  - Sponsor: Pending

- **CCT5025**
  - Phase III
  - bb2121 vs SoC Triplet Regimens in Relapsed & Refractory Multiple Myeloma (RRMM) (KarMMa-3)
  - PI: Liedtke
  - Sponsor: Pending

- **BMT362**
  - Phase II
  - MGTA-145 +/- Plerixafor in the Mobilization of HSCs for Autologous Transplantation in MM
  - PI: Sidana
  - Stanford

**KEY**

- Pending
- Open for Enrollment
- Optional Path
- Extension Study
- Immunotherapy
- Link
- Trial Posting
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu